A Prospective Open-label Trial Examining the Efficacy and Safety of Anifrolumab for Hidradenitis Suppurativa (HS)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Anifrolumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
Most Recent Events
- 13 Jun 2024 Status changed from not yet recruiting to recruiting.
- 22 Apr 2024 New trial record